Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR003210)
Formula
SVG example
Reactant Ketodarolutamide Product Darolutamide metabolite M31
Reactant Info Product Info
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003222 Darolutamide Ketodarolutamide Oxidation - Oxidation Darolutamide [1], [2], [3]
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003211 Ketodarolutamide Darolutamide metabolite M10 Conjugation - Glucuronidation Darolutamide [4]
MR003212 Ketodarolutamide Darolutamide metabolite M28 Unclear Darolutamide [4]
MR003215 Ketodarolutamide Darolutamide metabolite M33 Oxidation - N-Dealkylation Darolutamide [4]
MR003213 Ketodarolutamide Darolutamide metabolite M34 Oxidation - N-Dealkylation Darolutamide [4]
MR003214 Ketodarolutamide Darolutamide metabolite M36 Oxidation - N-Dealkylation Darolutamide [4]
Other MR(s) Related to The Product of This MR
Other MR(s) That Produce The Product of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003223 Darolutamide Darolutamide metabolite M31 Unclear Darolutamide [4]
Other MR(s) That Metabolize The Produtc of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003216 Darolutamide metabolite M31 Darolutamide metabolite M26 Unclear Darolutamide [4]
MR003217 Darolutamide metabolite M31 Darolutamide metabolite M30 Reduction - Reduction Darolutamide [4]
References
1 Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017.
2 Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer. Pharmaceutics. 2022 Oct 1;14(10):2101. doi: 10.3390/pharmaceutics14102101.
3 Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. Clin Pharmacokinet. 2022 Apr;61(4):565-575. doi: 10.1007/s40262-021-01078-y.
4 Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans Drug Metab Dispos. 2021 Jun;49(6):420-433. doi: 10.1124/dmd.120.000309.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.